Browsing Tag

UB312

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in…

Jason Junior Jun 22, 2023

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into…

Health

Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of…

Jason Junior Jan 12, 2022

DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with Parkinson’s disease (PD) has…